Who are POTASSIUM HYDROXIDE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Yupelri, Incruse Ellipta, Tudorza Pressair, Spiriva, Atrovent, Librax.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/potassium-hydroxide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

POTASSIUM HYDROXIDE — Competitive Intelligence Brief

POTASSIUM HYDROXIDE (POTASSIUM HYDROXIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic [EPC].

marketed Anticholinergic [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

POTASSIUM HYDROXIDE (POTASSIUM HYDROXIDE).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
POTASSIUM HYDROXIDE TARGET	POTASSIUM HYDROXIDE		marketed	Anticholinergic [EPC]
Yupelri	REVEFENACIN	Mylan Ireland Ltd	marketed	Anticholinergic [EPC]	Muscarinic acetylcholine receptor M3	2018-01-01
Incruse Ellipta	UMECLIDINIUM	Glaxo Grp England	marketed	Anticholinergic	Muscarinic acetylcholine receptor M4	2013-01-01
Tudorza Pressair	ACLIDINIUM BROMIDE	Covis	marketed	Anticholinergic	M3 receptors, beta 2 -adrenergic receptors	2012-01-01
Spiriva	TIOTROPIUM BROMIDE	Boehringer Ingelheim	marketed	Anticholinergic	Muscarinic acetylcholine receptor M3	2004-01-01
Atrovent	IPRATROPIUM		marketed	Anticholinergic	Muscarinic acetylcholine receptor M1	1986-01-01
Librax	CLIDINIUM	Roche	marketed	Anticholinergic	Muscarinic acetylcholine receptor M3	1982-01-01

Recent regulatory actions (last 90 days)

2026-02-23 — Atrovent · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic [EPC] class)

· 2 drugs in this class
Mylan Ireland Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). POTASSIUM HYDROXIDE — Competitive Intelligence Brief. https://druglandscape.com/ci/potassium-hydroxide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab